retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity is gaining attention in metabolic research for its activity on GIP, GLP-1, and receptors. In this carousel, we summarize recent clinical study findings related to weight management, type GLP-3 Dosing Protocol UAE: How

What If The GLP-1 Does Not Work

GLP-1/GIP medication is the health topic that everyones talking about: whos taking it, why theyre taking it, and who should actually be taking it in the first place

Protein shakes, Greek yogurt, cottage cheese, and lean meats become practical solutions for reaching targets despite reduced appetite

Compounded alternatives suit patients seeking cost-effective access, provider continuity with their primary care physician, genetic-informed personalization, or medication flexibility (e.g., dose titration, protocol stacking)

The phase 2 dose-ranging trial (NCT02970942) included 320 individuals with histologically proven MASH and hepatic fibrosis F1-F3, randomizing them 3:3:3:1:1:1 to daily subcutaneous administration of semaglutide 0.1, 0.2, or 0.4 mg, or placebo for 72 weeks [18]

Researchers found that semaglutide users were twice as likely to develop nAMD compared to non-users, even after adjusting for other health factors